comparemela.com

Corporate Affairsm News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Imlifidase demonstrated 90% patient survival and 82% graft survival at five years in extended pooled analysis with data

LUND, Sweden, Oct. 17, 2023 /PRNewswire/ Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in.

Uppsala lanUnited statesHansa biopharmahansa biopharmaTomas lorantLos angelesHansa biopharmaPrnewswire hansa biopharmaStanley jordanKlaus sindahlStephanie kenneyHmedides clinical trial programUppsala university hospitalSinai medical centerAmerican kidney fundEuropean unionEuropean medicines agency

Update on ConfIdeS Phase 3 trial of imlifidase in highly sensitized kidney transplant patients

LUND, Sweden, Oct. 11, 2023 /PRNewswire/ Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in.

United kingdomUnited statesDonato spotaPrnewswire hansa biopharmaMatthew shaulisKlaus sindahlStephanie kenneyHansa biopharmaDrug administrationLicense applicationNasdaq stockholmBiologics license applicationGlomerular filtration rateAntibody mediated rejectedSarepta duchenne muscular dystrophyInvestor relationsm

Update on ConfIdeS Phase 3 trial of imlifidase in highly sensitized kidney transplant patients

Update on ConfIdeS Phase 3 trial of imlifidase in highly sensitized kidney transplant patients
notimerica.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from notimerica.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesMatthew shaulisKlaus sindahlDonato spotaHansa biopharmaPrnewswire hansa biopharmaStephanie kenneyDrug administrationLicense applicationNasdaq stockholmBiologics license applicationGlomerular filtration rateAntibody mediated rejectedSarepta duchenne muscular dystrophyInvestor relationsm

Hansa Biopharma announces encouraging high-level results for first-in-human trial of HNSA-5487

LUND, Sweden, Oct. 9, 2023 /PRNewswire/ Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in.

Stephanie kenneyHansa biopharmaPrnewswire hansa biopharmaKlaus sindahlNasdaq stockholmNovel immunoglobulin cleaving enzymesRepeat dosingInvestor relationsmCorporate affairsm

Hansa Biopharma half year report 2023 (1)

LUND, Sweden, July 20, 2023 /PRNewswire/ Hansa Biopharma, the pioneer in immunomodulatory enzyme.

United kingdomUnited statesDonato spotaMatthew shaulisAdrian schreiberPhilipp enghardStephanie kenneyPrnewswire hansa biopharmaKlaus sindahlHansa biopharmaAustralian therapeutic goods administrationAmerican society of geneAcceptable mismatch programAcceptable mismatchAmerican societyCell therapy conference

vimarsana © 2020. All Rights Reserved.